Similar articles

• Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

  Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Pegram MD, et al. J Natl Cancer Inst. 2004 May 19;96(10):739-49. doi: 10.1093/jnci/djh131. J Natl Cancer Inst. 2004. PMID: 15150302
• Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

  Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ. Pegram MD, et al. J Natl Cancer Inst. 2004 May 19;96(10):759-69. doi: 10.1093/jnci/djh133. J Natl Cancer Inst. 2004. PMID: 15150304 Clinical Trial.
• Herceptin and chemotherapy combination active in advanced breast cancer.

  [No authors listed] [No authors listed] Cancer Biol Ther. 2004 Jun;3(6):489. doi: 10.4161/cbt.3.6.992. Cancer Biol Ther. 2004. PMID: 15717405 No abstract available.
• [Docetaxel (Taxotere) in combination with trastuzumab (Herceptin)].

  Ficorella C. Ficorella C. Tumori. 2001 Jan-Feb;87(1 Suppl 2):S10-8. Tumori. 2001. PMID: 11357872 Review. Italian. No abstract available.
• Interaction between Herceptin and taxanes.

  Diéras V, Beuzeboc P, Laurence V, Pierga JY, Pouillart P. Diéras V, et al. Oncology. 2001;61 Suppl 2:43-9. doi: 10.1159/000055401. Oncology. 2001. PMID: 11694787 Review.